The similar clinical manifestations in both patients, with cerebellar ataxia as the main complaint, inflammation of CSF, and effectiveness of immunotherapy, suggest that anti-EEF1D autoantibodies can potentially be used as biomarkers in ACA. The gene discussed is EEF1D; the disease is cerebellar ataxia.